Harrow vs MannKind
HROW and MNKD side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How HROW and MNKD compare
MannKind is the larger company, worth 1.2 times as much as Harrow ($1.3B against $1.1B).
MannKind grew revenue faster over the last twelve months (31.7% versus 21.3% for Harrow).
Harrow keeps more of each dollar of sales as profit, with a net margin of −9.4% compared with −18.1% at MannKind.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | HROW | MNKD |
|---|---|---|
| Size and price | ||
| Market cap | $1.1B | $1.3B |
| Share price | $30.12 | $4.13 |
| Change, 1 year | −21.6% | −21.3% |
| Change, 5 years | 179% | −13.1% |
| Beta (5Y) | 1.37 | 1.07 |
| Employees | 373 | 241 |
| StockData Score | ||
| Total score | 6 | 6 |
| Valuation score | 0 | 1 (better) |
| Growth score | 3 (better) | 2 |
| Performance score | 2 | 2 |
| Health score | 1 | 1 |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/S | 3.7× | 3.2× (better) |
| P/B | 38.7× | – |
| EV/EBITDA | – | 87.0× |
| FCF yield | −1.8% (better) | −5.9% |
| Fair value | – | $1.11 |
| Margin of safety | – | −273% |
| Growth | ||
| Revenue growth (TTM) | 21.3% | 31.7% (better) |
| Revenue growth, 5Y average | 41.0% (better) | 39.9% |
| Net income growth (TTM) | – | −356% |
| EPS growth (TTM) | – | −330% |
| Profitability | ||
| Gross margin | 73.5% | 88.6% (better) |
| Operating margin | −2.0% (better) | −2.9% |
| Net margin | −9.4% (better) | −18.1% |
| FCF margin | −6.7% (better) | −19.0% |
| Return on equity | −74.8% | – |
| Return on invested capital | −2.1% | – |
| Financial health | ||
| Debt / equity | 10.03 | – |
| Interest coverage | −0.3× (better) | −0.3× |
| Current ratio | 2.29 (better) | 2.22 |
| Altman Z-score | 2.07 (better) | −4.52 |
| Piotroski F-score | 5 | 5 |
| Dividends and buybacks | ||
| Shareholder yield | 0.00% | 0.00% |
| Ownership | ||
| Held by institutions | 57.4% | 56.7% |
| Held by insiders | 14.2% | 2.5% |
| Insider net buying, 12 months | −$9.2M | −$2.9M (better) |
| Short interest, % of float | 22.1% | 8.4% |
Go deeper
- HROW stock overview
- HROW income statement
- HROW valuation and score
- MNKD stock overview
- MNKD income statement
- MNKD valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.